SCM Selected for Ketensin Supply

ProStrakan Group has awarded SCM Pharma a five-year contract for the ongoing supply of its licensed product, Ketensin. SCM will be responsible for the filling of the 2ml and 10ml vial presentations, sterilization, finished product testing and supply of the product.

Ketensin is indicated for the treatment of hypertensive crisis during and after surgery, and is marketed by ProStrakan in the Netherlands. It is a niche product and requires relatively limited supply.

David Traynor, senior vice president of manufacturing and pharmaceutical sciences at ProStrakan, said, “With regular demand for Ketensin in the Netherlands, we required a manufacturing partner that could not only sterile fill into various sizes of vials and test the finished products, but that could reliably deal with smaller commercial quantities. Having completed the technical transfer and geared-up for the Process Qualification batch already, we have been impressed by the customer interaction, willingness and technical ability demonstrated by SCM Pharma and look forward to working with the team on an ongoing basis.”

Dianne Sharp, managing director at SCM Pharma, remarked, “We are delighted to have secured a long-term deal with such a fast-growing high-profile client and are looking forward to meeting ProStrakan’s supply needs for Ketensin over the next few years and beyond. This type of product not only complements our core capability of filling and sterilizing small batches of glass vials but also makes optimum use of the in-house microbiology, chemistry and sterility testing services that our facility offers clients.”

This contract follows the opening of SCM Pharma’s first U.S. office at the end of last year, aimed at growing the company’s export revenue and better serving U.S.-based clients.


Click here to learn more about SCM Pharma